Insider filing · ALMS

James B. Tananbaum bought $3.1M of Alumis (ALMS)

Executed Nov 17 2025, disclosed Nov 20 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 19 2025), the stock returned +73.6% (delay-adjusted); from the execution session (Nov 17 2025), +106.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

JT James B. Tananbaum Director profile →

James B. Tananbaum (Director) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales), most often in Alumis Inc. (ALMS). Across 4 priced purchase filings, the average 21-session return was +61.1% from execution and +48.9% from disclosure (delay-adjusted; derived). The largest single filing was $7.0M of ALMS (411,764 sh across 2 lots, as filed), executed Jan 8.

ALMS Alumis Inc. ALMS · Healthcare · 24 filings in 24 months ticker →

Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→